Autosomal dominant Charcot‑Marie‑Tooth disease type 2E is a genetic neuropathy that affects the peripheral nerves. People with this condition often notice weakness in the feet and ankles, foot drop, high arches, and numbness or tingling in the legs and hands. Symptoms usually start in childhood or early adulthood and tend to progress slowly over a lifetime. Most people with Autosomal dominant Charcot‑Marie‑Tooth disease type 2E have a normal life span, but mobility and hand function can be affected. Treatment focuses on management with physical and occupational therapy, ankle‑foot orthoses, pain control, and sometimes surgery for foot deformities.
Overview
Autosomal dominant charcot-marie-tooth disease type 2eSymptoms
Autosomal dominant Charcot‑Marie‑Tooth disease type 2E causes gradual nerve problems: tingling, numbness, and foot weakness that can lead to foot drop, high arches, poor balance, and cramps. Early symptoms of autosomal dominant Charcot‑Marie‑Tooth disease type 2E often begin in adolescence.
Outlook and prognosis
Many people with autosomal dominant Charcot–Marie–Tooth disease type 2E (CMT2E) stay active for years, with symptoms that change slowly. Nerve weakness can progress, bringing balance issues and foot deformities, but life expectancy is typically near normal. Regular rehab, bracing, and fall‑prevention support independence.
Causes and risk factors
Autosomal dominant Charcot‑Marie‑Tooth disease type 2E results from NEFL gene mutations, usually inherited from an affected parent, or less often new. Main risk is family history; diabetes, alcohol misuse, vitamin deficiencies, and neurotoxic drugs can worsen neuropathy.
Genetic influences
Genetics play a central role in autosomal dominant Charcot‑Marie‑Tooth disease type 2E. A single altered gene copy can cause the condition, and it often runs in families. New (de novo) variants can also arise, so genetic testing helps confirm diagnosis and guide relatives.
Diagnosis
Doctors start with clinical features and family history, then nerve conduction studies and EMG to show an axonal neuropathy. Genetic tests confirming an NEFL variant provide the genetic diagnosis of autosomal dominant Charcot‑Marie‑Tooth disease type 2E.
Treatment and drugs
Treatment for autosomal dominant Charcot‑Marie‑Tooth disease type 2E focuses on nerve support, mobility, and pain control. Many benefit from physical and occupational therapy, custom ankle‑foot orthoses, foot care, and fall‑prevention. Doctors may use neuropathic pain medicines; surgery can address severe foot deformities.
Symptoms
Changes in foot strength, balance, or hand skills can make walking longer distances, climbing stairs, or buttoning a shirt harder than before. Autosomal dominant charcot-marie-tooth disease type 2e affects the long nerves to the legs and arms, leading to muscle weakness and reduced sensation. Features vary from person to person and can change over time. Common early features of autosomal dominant charcot-marie-tooth disease type 2e include frequent ankle rolling, high arches, and trouble lifting the front of the foot.
In autosomal dominant charcot-marie-tooth disease type 2e, the front of the foot doesn’t lift well while walking. Toes may catch on the ground, leading to trips or a higher-stepping gait. Stairs and uneven ground can feel risky.
The arches of the feet become unusually high. This can make shoes hard to fit and put pressure on the ball or heel. Painful calluses or hammertoes may follow.
With autosomal dominant charcot-marie-tooth disease type 2e, grip can feel weaker and fine tasks like buttoning, typing, or turning keys take more effort. Jars or zippers may become frustrating. Over time, hand muscles can look thinner.
Reduced feeling in the feet and sometimes the hands is common. You may not notice small injuries or temperature changes as easily. Tingling or burning sensations can come and go.
How people usually first notice Autosomal dominant charcot-marie-tooth disease type 2e?
Many first notice something is off in their teens or early adulthood when tripping more often, ankles feeling weak, or toes starting to lift less with walking; these early changes reflect the first signs of autosomal dominant Charcot-Marie-Tooth disease type 2E (CMT2E). Families sometimes recognize a pattern—perhaps a parent or grandparent with high arches, thin calves, or long-standing ankle weakness—which can prompt earlier evaluation. Doctors often first notice reduced reflexes at the ankles, mild foot deformities like high arches or hammertoes, and length‑dependent weakness or numbness in the feet before the hands, leading to nerve testing and genetic confirmation.
Types of Autosomal dominant charcot-marie-tooth disease type 2e
Autosomal dominant Charcot–Marie–Tooth disease type 2E (CMT2E) is a hereditary neuropathy that affects the long nerves to the feet and hands. It belongs to the axonal forms of CMT and is most often linked to changes in the NEFL gene, which can lead to different patterns of weakness, sensation changes, and progression. People may notice different sets of symptoms depending on their situation. When discussing types of CMT2E, clinicians focus on recognized NEFL-related clinical variants and the age when symptoms begin, since these can shape how the condition feels day to day.
Early-onset variant
Symptoms start in childhood with delayed walking, frequent tripping, or clumsiness. Weakness and foot deformities like high arches can appear sooner and progress more quickly.
Adolescent-onset variant
Changes emerge in the teen years with ankle weakness, difficulty running sports, and reduced sensation in the feet. Hand weakness may follow later, affecting tasks like fastening buttons.
Adult-onset variant
Symptoms begin in the 20s to 40s with slowly progressive foot drop and numbness in the toes. Many remain active for years, but long walks or standing may become harder over time.
Motor-predominant pattern
Leg and foot weakness stands out more than numbness or tingling. Hand grip may weaken later, while pain and sensory loss are relatively milder.
Sensory-predominant pattern
Numbness, vibration loss, and balance problems are more noticeable than weakness. People may develop burning or tingling in the feet before clear muscle loss is seen.
NEFL mutation subtypes
Different NEFL gene changes are linked to variable severity and age at onset. These variants of CMT2E can influence whether symptoms are mainly motor, mainly sensory, or mixed.
What genetics can tell you about symptoms
Certain NEFL gene changes in autosomal dominant Charcot-Marie-Tooth disease type 2E can cause early walking delays, foot drop, and distal muscle weakness with numbness. Some variants lead to earlier onset and more severe nerve damage, while others cause milder, slower-progressing symptoms.
Causes and risk factors
Autosomal dominant Charcot-Marie-Tooth disease type 2E is caused by a change in the NEFL gene.
Most people inherit it from an affected parent, and each child has a 50% chance of getting the same change.
Sometimes the change is new in a child, and severity and age of onset can vary even within a family.
Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
Alcohol misuse, smoking, and nerve-toxic medicines like vincristine can worsen nerve damage and may make early symptoms of autosomal dominant Charcot-Marie-Tooth disease type 2E show sooner.
Environmental and biological risk factors
Autosomal dominant Charcot-Marie-Tooth disease type 2E typically arises from changes present very early in development, so risks are mostly built-in rather than triggered after birth. This section highlights internal and external factors that may influence how likely it is to occur in a family. Doctors often group risks into internal (biological) and external (environmental). Understanding these can also help you stay alert to early symptoms of Autosomal dominant Charcot-Marie-Tooth disease type 2E without causing unnecessary worry.
Conception at an older paternal age is linked with a higher chance of new biological changes forming in sperm. This slightly raises the chance that Autosomal dominant Charcot-Marie-Tooth disease type 2E appears for the first time in a child. Most conceptions at older ages still result in children without this condition.
Very high doses of ionizing radiation to a parent’s pelvis or testes/ovaries can damage reproductive cells. Safety standards keep medical and workplace exposures far below these levels. If such exposure did occur, a specialist can advise on timing and any need for added precautions before trying to conceive.
No common environmental exposure has been shown to cause this condition. Everyday surroundings, typical air pollution levels, and routine household products have not been linked to higher risk.
Genetic risk factors
In autosomal dominant Charcot-Marie-Tooth disease type 2E (CMT2E), most cases stem from a single faulty copy of the NEFL gene, which brings a 50% chance of passing it to each child. Some people are the first in their family when the change arises new in the egg or sperm. Severity and age at onset can differ even within the same family; Risk is not destiny—it varies widely between individuals. When questions come up about family risk or testing, genetic testing for autosomal dominant Charcot-Marie-Tooth disease type 2E can clarify who carries the change.
NEFL gene variants: Changes in the NEFL gene disrupt nerve fibers and are the established cause of CMT2E. Most people have a single altered copy that affects peripheral nerves.
Dominant inheritance: A parent with the NEFL change has a 50% chance of passing it to each child. The chance is the same for all sexes.
De novo variants: Sometimes the NEFL change appears for the first time in someone with no family history of CMT2E. This means a parent may not carry the change, but the affected person can pass it to future children.
Germline mosaicism: Rarely, a parent carries the NEFL change only in some egg or sperm cells while blood testing is negative. This raises the chance of another child with CMT2E slightly above the general population.
Variable severity: The same NEFL change can lead to different ages of onset and levels of weakness in relatives. This variation affects how CMT2E shows up person to person.
Variant-specific patterns: Different NEFL changes have been linked to axonal or demyelinating patterns on nerve testing, overlapping with CMT1F in some families. Certain variants are associated with earlier onset, but predictions for one person remain uncertain.
Family history: Having a first-degree relative with a confirmed NEFL variant strongly increases personal risk of CMT2E. Cascade testing can pinpoint who carries the change.
Sex and ancestry: Because NEFL is on a non-sex chromosome, risk is similar for all sexes. CMT2E occurs across many ancestries worldwide.
Lifestyle risk factors
Lifestyle choices do not cause this condition, but they can influence symptom severity, function, and risk of complications. Thoughtful daily habits may support mobility, reduce falls, and ease fatigue and pain. The points below focus on how lifestyle affects Autosomal dominant charcot-marie-tooth disease type 2e in practical ways.
Low-impact aerobic exercise and gentle strength training can help preserve muscle function and endurance. Consistent movement may improve balance and reduce fatigue.
Repetitive high-impact or maximal-load activities can worsen ankle instability and raise fall risk. Pacing and avoiding overexertion may limit symptom flare-ups.
Daily calf, hamstring, and ankle stretches can reduce contracture risk and support gait efficiency. Postural exercises may ease compensatory back or hip strain from foot drop.
Shoes with firm heel counters, wide toe boxes, and good grip can improve stability and reduce tripping. Consistent use of orthotics or ankle-foot supports may decrease falls and energy cost of walking.
Risk prevention
Autosomal dominant Charcot-Marie-Tooth disease type 2E is inherited, so you can’t prevent the condition itself, but you can lower risks of falls, pain, and loss of function. Noticing early symptoms of autosomal dominant Charcot-Marie-Tooth disease type 2E can lead to earlier support, which often protects mobility. Even if you can’t remove all risks, prevention can reduce their impact. For family planning, genetic options may help avoid passing on the condition.
A genetics visit can clarify your personal and family risk of autosomal dominant Charcot-Marie-Tooth disease type 2E. Discuss options like prenatal testing or IVF with embryo testing to avoid passing on the variant.
Getting evaluated when weakness, frequent ankle sprains, or foot changes appear allows earlier supports. Early orthotics and therapy can slow secondary problems like joint stiffness and falls.
Ongoing visits with neurology and rehabilitation track strength, balance, and foot structure. Adjusting braces, therapy plans, and medications in time can prevent avoidable setbacks.
Targeted balance, core, and ankle exercises help stabilize weak muscles. A therapist familiar with Charcot-Marie-Tooth can tailor a program that protects joints and reduces falls.
Transmission
Autosomal dominant charcot-marie-tooth disease type 2e is a genetic condition, not an infection, so it isn’t contagious and you can’t catch it from others. It is inherited in an autosomal dominant way: if a parent carries the gene change, each child has a 50% chance of inheriting it. Sometimes the change appears for the first time in a child (a new mutation), so there may be no earlier family history. This pattern reflects the genetic transmission of Autosomal dominant charcot-marie-tooth disease type 2e.
When to test your genes
Consider genetic testing if you have progressive distal weakness or numbness, a family history of similar symptoms, or early signs of axonal neuropathy on nerve studies. Testing can confirm autosomal dominant CMT2E, clarify your personal risk, and guide surveillance, therapy choices, and family planning. Discuss timing with a genetics‑savvy neuromuscular specialist.
Diagnosis
For many, the first step comes when everyday activities start feeling harder—like tripping more often or noticing weaker ankles. Getting a diagnosis is often a turning point toward answers and support. The genetic diagnosis of Autosomal dominant charcot-marie-tooth disease type 2e usually combines a hands-on exam with nerve tests and DNA analysis. Doctors aim to confirm the pattern is inherited and rule out more common causes of nerve damage.
A clinician checks muscle strength, reflexes, sensation, and foot shape. Findings such as foot drop, high arches, or reduced ankle reflexes can point toward a hereditary nerve condition. Patterns on exam help distinguish axonal from other types of neuropathy.
A detailed family and health history can help show an autosomal dominant pattern across generations. Your provider may ask who else in the family has similar symptoms and at what age they began. This can guide which genes to test first.
Small electrical pulses measure how well signals travel along the nerves. In CMT2E, speeds may be near-normal but signal strength is reduced, suggesting axonal damage. These tests also help rule out demyelinating forms.
A thin needle records electrical activity in muscles. EMG can show changes that support an axonal neuropathy. Results complement nerve conduction studies to narrow the diagnosis.
Stages of Autosomal dominant charcot-marie-tooth disease type 2e
Autosomal dominant charcot-marie-tooth disease type 2e does not have defined progression stages. It typically changes slowly over many years, and the pattern can differ from person to person (even within the same family), so healthcare teams track day-to-day function rather than assigning stages. Doctors usually start with a conversation about early symptoms of Autosomal dominant charcot-marie-tooth disease type 2e and any family history, followed by a hands-on check of strength, reflexes, and sensation. Nerve tests (like nerve conduction studies and EMG) and genetic testing can confirm the diagnosis, and follow-up visits focus on changes in walking, balance, hand strength, and foot shape over time.
Outlook and prognosis
Living with Autosomal dominant Charcot-Marie-Tooth disease type 2E (CMT2E) usually means a slow, progressive change in strength and sensation, most noticeable in the feet and lower legs at first, then sometimes the hands. Many people ask, “What does this mean for my future?”, and the short answer is that most people with CMT2E remain mobile for many years, often with supports like ankle–foot braces, custom shoes, or occasional use of a cane during flares or fatigue. Early symptoms of CMT2E can include tripping on uneven ground, frequent ankle sprains, or hand cramps when buttoning a shirt, and these may gradually advance over decades rather than months.
Doctors call this the prognosis—a medical word for likely outcomes. For most, CMT2E does not shorten life expectancy, and serious complications affecting breathing or the heart are uncommon, though periodic checks are sensible. Weakness and balance issues can raise the risk of falls and fractures, and foot deformities may lead to calluses or ulcers, but proactive foot care and physical therapy can lower those risks. Some people experience relatively stable function for long stretches, while others notice slow, steady change, and cold weather, illness, or overexertion can temporarily make symptoms feel worse.
Looking at the long-term picture can be helpful. With ongoing care, many people maintain work, family life, and hobbies by pacing activities, using adaptive tools, and staying active within safe limits. There’s no cure yet, but symptom-focused care—bracing, therapy, pain control, and orthopedic support when needed—often preserves mobility and independence. Talk with your doctor about what your personal outlook might look like, especially if you’re considering genetic testing, planning a pregnancy, or noticing new or faster-changing symptoms.
Long-term effects
Autosomal dominant Charcot-Marie-Tooth disease type 2E usually progresses slowly over many years, with changes that build little by little. Long-term effects vary widely, and the pace can differ even within the same family. Most people keep their independence, and overall life expectancy is typically near typical. Some recall early symptoms of autosomal dominant Charcot-Marie-Tooth disease type 2E like frequent ankle sprains or tripping before long-term weakness becomes clear.
Weakness often starts in the feet and ankles, leading to foot drop and frequent tripping. Over time, it can creep up the legs and later affect the hands.
Numbness, tingling, and reduced vibration sense often begin in the toes and feet. These changes may spread upward, making it harder to feel the ground or detect temperature.
Unsteady walking is common, especially on uneven ground or in low light. The risk of stumbles and falls can increase as sensation and strength decline.
High arches and hammertoes may develop and become more noticeable over time. These structural changes reflect the long-standing muscle imbalance in the feet.
How is it to live with Autosomal dominant charcot-marie-tooth disease type 2e?
Living with autosomal dominant Charcot–Marie–Tooth disease type 2E often means adapting to slowly changing nerve and muscle function in the lower legs and feet, sometimes the hands, with fatigue, tripping, ankle instability, or hand weakness shaping how you move through your day. Many build routines around supportive footwear, braces, paced activity, and hand-friendly tools, balancing independence with smart energy conservation. Family, friends, and coworkers may notice you taking extra time on stairs or needing help with fine tasks, and clear communication about what helps—like accessible setups or rest breaks—can ease strain on everyone. Because it’s inherited, relatives may weigh genetic testing and future planning, and staying connected with neurology, physical therapy, and peer support often makes daily life more confident and manageable.
Treatment and drugs
Treatment for autosomal dominant Charcot–Marie–Tooth disease type 2E focuses on easing symptoms, protecting function, and supporting mobility over time; there’s currently no cure, but many people manage their symptoms and live fulfilling lives. Care usually includes regular physical therapy to keep muscles strong and flexible, occupational therapy to adapt daily tasks, and properly fitted ankle–foot orthoses or custom shoes to improve balance, reduce tripping, and relieve foot pain. Doctors sometimes recommend a combination of lifestyle changes and drugs, such as pain relievers for nerve pain, medications for muscle cramps if needed, and treatment for related issues like sleep problems or mood changes. Surgery can help in selected cases with severe foot deformities that limit walking, while fall-prevention strategies, stretching, and low-impact exercise (like swimming or cycling) often support day-to-day comfort. Research is ongoing, so ask your doctor about clinical trials and keep track of how you feel, and share this with your care team to fine-tune your plan as needs change.
Non-drug treatment
Non-drug care focuses on keeping you active, steady on your feet, and comfortable day to day. Non-drug treatments often lay the foundation for long-term function and safety. Recognizing early symptoms of Autosomal dominant charcot-marie-tooth disease type 2e can help start supportive care sooner. Plans are individualized and usually combine movement therapies with bracing and practical home adaptations.
Gentle strengthening, stretching, and gait training help maintain mobility and reduce stiffness. A therapist can tailor exercises to foot drop, ankle weakness, and balance issues. Regular tune-ups adjust the plan as needs change.
Hand and arm exercises, energy-saving techniques, and workspace tweaks make daily tasks easier. Splints or adaptive tools can support grip and fine-motor tasks like buttoning or writing. Home safety advice reduces strain and fall risk.
Light braces support weak ankle muscles and foot drop, improving toe clearance and stability. They can reduce tripping and help you walk more efficiently. Ask your doctor which non-drug options might be most effective for your goals and activities.
Shoes with firm heels, wide toe boxes, and good traction improve stability. Custom inserts or carbon-fiber plates can enhance push-off and comfort. A podiatrist can guide fit to prevent pressure spots.
Your genes may have an impact on how drugs work for you
Medicines for autosomal dominant Charcot‑Marie‑Tooth disease type 2E can work differently depending on your genes, which shape nerve protein function and how your body processes drugs. Pharmacogenetic testing may guide safer dosing, reduce side effects, and improve symptom control.
Pharmacological treatments
For autosomal dominant Charcot-Marie-Tooth disease type 2E (CMT2E), there’s no medicine that reverses the nerve damage yet, so drug treatment focuses on easing symptoms like nerve pain and cramps. Doctors often combine non-drug care with medications for nerve pain in Charcot-Marie-Tooth disease to improve day-to-day comfort and sleep. Choices are tailored to your symptoms and health history, and many are used “off label.” Not everyone responds to the same medication in the same way.
Gabapentin and pregabalin can calm nerve pain and burning sensations. They may also help with sleep when pain flares at night. Drowsiness and dizziness are the most common side effects.
Duloxetine or venlafaxine can ease neuropathic pain and may help mood when chronic pain weighs on you. Nausea or sleep changes can occur, and dose adjustments are sometimes needed.
Amitriptyline or nortriptyline can reduce stabbing or tingling pain, especially at night. Dry mouth and constipation are common, and a lower dose is often used at first.
Lidocaine 5% patches or capsaicin creams can target small, painful areas without affecting the whole body. Skin irritation or numbness can happen but usually settles.
Genetic influences
In autosomal dominant Charcot-Marie-Tooth disease type 2E, most cases stem from a single harmful change in a gene called NEFL, which helps keep long nerve fibers stable. Because it is autosomal dominant, having one altered copy is enough to cause the condition, and each child of an affected parent has a 50% (1 in 2) chance of inheriting it. Family history is one of the strongest clues to a genetic influence. Some people develop CMT2E for the first time in a family because of a new gene change that is not present in either parent. Even among relatives with the same NEFL change, symptoms and the age when problems start can vary widely. Genetic testing for autosomal dominant Charcot-Marie-Tooth disease type 2E can confirm the NEFL change and support counseling about family planning and care.
Is Autosomal dominant charcot-marie-tooth disease type 2e genetic?
Genetics play a central role in autosomal dominant Charcot‑Marie‑Tooth disease type 2E. A single altered gene copy can cause the condition, and it often runs in families. New (de novo) variants can also arise, so genetic testing helps confirm diagnosis and guide relatives.
Pharmacogenetics—how genetics influence drug effects
For people living with autosomal dominant Charcot‑Marie‑Tooth disease type 2E (CMT2E), care today focuses on easing symptoms like nerve pain and muscle cramps; there isn’t yet an approved treatment that directly targets the NEFL gene change. The CMT2E gene itself usually doesn’t determine which pain medicine will work, but other common genes that handle medicines can shape safety and dosing. For example, differences in CYP2D6 can change how codeine or tramadol are converted to their active form—people who break them down very quickly may be more prone to side effects, while those who break them down slowly may get little pain relief. Tricyclics such as amitriptyline or nortriptyline, often used for nerve pain or sleep, are guided by CYP2D6 and CYP2C19 results, which can point to a lower starting dose or a different choice. NSAIDs, including celecoxib and some others for pain, are influenced by CYP2C9; some results call for dose reduction or switching to reduce bleeding or other side effects. If carbamazepine or oxcarbazepine is considered, checking HLA‑B*15:02 and HLA‑A*31:01 can help avoid rare but serious skin reactions, especially in people with East or Southeast Asian ancestry. By contrast, gabapentin and pregabalin are not meaningfully affected by known pharmacogenetic factors and are cleared by the kidneys. Alongside your medical history and current medicines, genetic testing can help personalize pain management and limit trial and error.
Interactions with other conditions
Day to day, having another health issue on top of nerve problems can make walking, hand tasks, and fatigue feel tougher. In autosomal dominant Charcot-Marie-Tooth disease type 2E (CMT2E), conditions that also affect nerves—like diabetes, low thyroid levels, or vitamin B12 deficiency—can add to numbness, balance trouble, and cramping. Doctors call it a “comorbidity” when two conditions occur together. Alcohol overuse and kidney disease may further irritate nerves, and joint problems or arthritis can compound pain and mobility limits.
Some medicines are hard on nerves; certain chemotherapy drugs—especially vincristine and some taxanes—can cause sudden worsening, so it’s important that cancer teams know about CMT2E before treatment begins. Immune-related nerve inflammation (often called CIDP) can occasionally appear in someone with CMT2E and muddy the picture, because early symptoms of autosomal dominant Charcot-Marie-Tooth disease type 2E can look similar; however, treatments differ, and accurate diagnosis matters. Infections that inflame nerves, uncontrolled blood sugar, or severe hypothyroidism can “turn up the volume” on weakness and numbness until the other condition is treated. Interactions can look very different from person to person, so coordinated care across neurology, primary care, endocrinology, and, when needed, oncology helps keep plans safe and tailored.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of slow-worsening weakness in the lower legs and feet, then later in the hands—grandparents who tripped easily, parents with high arches or thin calves, children who ran a bit differently. Long before tests existed, people with what we now call autosomal dominant Charcot‑Marie‑Tooth disease type 2E (CMT2E) were described as “having weak ankles” or “poor balance,” with stories passed through generations.
From early theories to modern research, the story of CMT has unfolded in steps. In the late 1800s, doctors Charcot, Marie, and Tooth separately documented a hereditary nerve condition that caused progressive weakness and sensory changes. At that time, all forms were grouped together. As clinical observation improved in the 20th century, specialists noticed that some people had nerve damage mainly in the long fibers themselves rather than in the protective covering. This pattern was labeled “type 2,” or axonal CMT, based on how the nerves looked and conducted signals on testing.
With each decade, the picture sharpened. Nerve conduction studies and biopsies helped separate subtypes by what doctors could measure, but families still heard only broad labels. The shift came with advances in genetics in the 1990s and 2000s, when researchers tied specific gene changes to distinct CMT patterns. One of these genes, NEFL, which provides a key building block for nerve fibers, was linked to a subset of axonal CMT. When a single altered copy of NEFL was enough to cause the condition in a family, it was classified as autosomal dominant CMT type 2E.
Initially understood only through symptoms, later CMT2E could be recognized by its inheritance pattern across generations—often affecting a parent and child—and by genetic testing that confirmed a NEFL variant. This helped explain why some relatives had earlier onset or more noticeable balance issues, while others had milder changes despite the same family diagnosis. It also clarified why doctors sometimes saw both motor and sensory involvement even within one family.
In recent decades, awareness has grown as genetic testing became more accessible in Europe, North America, and beyond. Registries and natural history studies have begun to track how CMT2E changes over time, guiding care and rehabilitation. Historical differences highlight why older medical notes might use broader labels like “CMT type 2,” while newer records specify “CMT2E (NEFL‑related).” Knowing the condition’s history helps families understand how naming has evolved from observation to mechanism, and why today’s testing can offer more precise answers than were possible for earlier generations.